$Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment$

Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment

Regorafenib (Stivarga, BAY 73-4506; Bayer Pharma AG, Berlin, Germany) is a novel oral multikinase inhibitor that blocks the activity of several protein kinases. However, few guidelines exist for novel biomarkers to select patients who will likely benefit from regorafenib treatment. Metastatic colore...

Full description

Bibliographic Details
Main Authors:	Min-Sang Lee, Hee Jin Cho, Jung Yong Hong, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Yong Beom Cho, Seung Tae Kim
Format:	Article
Language:	English
Published:	SAGE Publishing 2020-11-01
Series:	Therapeutic Advances in Medical Oncology
Online Access:	https://doi.org/10.1177/1758835920965842

Similar Items

The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice
by: Yoon SE, et al.
Published: (2018-12-01)

Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial
by: Seung Tae Kim, et al.
Published: (2019-04-01)

First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients
by: Seung Tae Kim, et al.
Published: (2020-06-01)

Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal Cancer.
by: Yoojoo Lim, et al.
Published: (2015-01-01)

The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer
by: Su Jin Lee, et al.
Published: (2018-04-01)

Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line
by: Seung Tae Kim, et al.
Published: (2018-11-01)

Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors
by: Hana Kim, et al.
Published: (2021-02-01)

Prolonged Response to Regorafenib in a Patient with Iodine Refractory Thyroid Cancer
by: Selina K. Wong, et al.
Published: (2019-10-01)

gene amplification in patients with metastatic cancer
by: Su Jin Lee, et al.
Published: (2017-09-01)

Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers
by: Su Jin Lee, et al.
Published: (2020-01-01)

Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
by: Cheol-Hyung Lee, et al.
Published: (2020-07-01)

Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer
by: Jung Yong Hong, et al.
Published: (2021-08-01)

Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma
by: Won‐Mook Choi, et al.
Published: (2020-07-01)

Unique perception of clinical trials by Korean cancer patients
by: Lee Su Jin, et al.
Published: (2012-12-01)

Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer
by: Seung Tae Kim, et al.
Published: (2015-02-01)

Regorafenib Regulates AD Pathology, Neuroinflammation, and Dendritic Spinogenesis in Cells and a Mouse Model of AD
by: Kyung-Min Han, et al.
Published: (2020-07-01)

Identification of FGFR3-TACC3 gene fusion in metastatic gastric cancer
by: Youjin Kim, et al.
Published: (2017-12-01)

Prognostic significance of sealed-off perforation in colon cancer: a prospective cohort study
by: Kil-yong Lee, et al.
Published: (2018-12-01)

Selective colony area method for heterogeneous patient-derived tumor cell lines in anti-cancer drug screening system.
by: Jang Ho Cho, et al.
Published: (2019-01-01)

Successful resuscitation of refractory ventricular fibrillation with double sequence defibrillation
by: SungJoon Park, et al.
Published: (2021-02-01)

Results from the safety interim analysis of the adjuvant chemoradiotherapy in stomach tumors 2 trial: a multicenter, randomized phase III clinical trial
by: Se Hoon Park, et al.
Published: (2019-03-01)

BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells
by: Hee Kyung Kim, et al.
Published: (2016-06-01)

Serrated Polyposis Syndrome with a Synchronous Colon Adenocarcinoma Treated by an Endoscopic Mucosal Resection
by: Sang Hoon Lee, et al.
Published: (2020-09-01)

Long Non-coding RNA MIR570MG Causes Regorafenib Resistance in Colon Cancer by Repressing miR-145/SMAD3 Signaling
by: Fang Wei, et al.
Published: (2020-03-01)

Comparison of microbiota in the cloaca, colon, and magnum of layer chicken.
by: Seo-Jin Lee, et al.
Published: (2020-01-01)

A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer.
by: Yuji Miyamoto, et al.
Published: (2020-01-01)

The use of regorafenib in colorectal cancer
by: Marina I Sekacheva, et al.
Published: (2019-06-01)

Right colon perforation is associated with the higher mortality compared to left colon perforation
by: Kil-yong Lee, et al.
Published: (2021-07-01)

Interaction Between Sex and Organic Anion‐Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib‐N‐Oxide and Regorafenib‐Glucuronide in Mice
by: Qiang Fu, et al.
Published: (2019-07-01)

Fatal Acute Liver Failure as a Consequence of Regorafenib Treatment in a Metastatic Colon Cancer
by: Dominique Béchade, et al.
Published: (2017-08-01)

Colonic Diffuse Large B-cell Lymphoma Hidden in Actinomycosis
by: Sang Hoon Lee, et al.
Published: (2019-07-01)

Complete Response to the Sequential Treatment with Regorafenib Followed by PD-1 Inhibitor in a Sorafenib-Refractory Hepatocellular Carcinoma Patient
by: Zhang E, et al.
Published: (2020-12-01)

Endoscopic Resection of Colonic Vascular Ectasia Mimicking as a Pedunculated Polypoid Lesion
by: Sang Hoon Lee, et al.
Published: (2019-06-01)

Refractory acute suppurative thyroiditis secondary to pyriform sinus fistula
by: Jee Hyue Seo, et al.
Published: (2014-06-01)

Genomic Multiplication and Drug Efflux Influence Ketoconazole Resistance in Malassezia restricta
by: Minji Park, et al.
Published: (2020-04-01)

Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening
by: Sung Hee Lim, et al.
Published: (2019-11-01)

Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer
by: Seung Tae Kim, et al.
Published: (2015-08-01)

Multicenter Retrospective Analysis of the Effectiveness and Safety of Rituximab in Korean Patients with Refractory Systemic Lupus Erythematosus
by: So-Young Bang, et al.
Published: (2012-01-01)

Triggering of Suicidal Erythrocyte Death by Regorafenib
by: Jens Zierle, et al.
Published: (2016-01-01)

Experience with regorafenib in the treatment of hepatocellular carcinoma
by: Alessandro Granito, et al.
Published: (2021-05-01)

Cannot write session to /tmp/vufind_sessions/sess_1cq8aoi93k7umv3h3p0v97u4qk